Public Health Impact of the Adjuvanted RSVPreF3 Vaccine for Respiratory Syncytial Virus Prevention Among Older Adults in the United States.

Daniel Molnar Elizabeth M La Frederik Verelst Sara Poston Jonathan Graham Laure-Anne Van Bellinghen Desmond Curran

Published in: Infectious diseases and therapy (2024)

These findings highlight the potential of the adjuvanted RSVPreF3 vaccine to substantially reduce RSV disease burden among US older adults aged ≥ 60 years.

Keyphrases

respiratory syncytial virus
public health
physical activity
risk factors
risk assessment
global health